--- title: "LENSAR (NASDAQ:LNSR) Stock Price Up 0.6% - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/275095758.md" description: "LENSAR (NASDAQ:LNSR) stock rose 0.6% to $12.28, with trading volume increasing by 262%. Analysts have mixed ratings, with Weiss Ratings maintaining a \"sell\" and Wall Street Zen upgrading to \"hold.\" The company reported a quarterly EPS of ($0.31), missing estimates, and revenue of $14.32 million, below expectations. Institutional investors hold 40.15% of shares, with notable increases from Brandes Investment Partners and Vanguard Group. LENSAR specializes in advanced laser systems for ophthalmic surgery, focusing on enhancing surgical accuracy in cataract treatment." datetime: "2026-02-06T08:28:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275095758.md) - [en](https://longbridge.com/en/news/275095758.md) - [zh-HK](https://longbridge.com/zh-HK/news/275095758.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275095758.md) | [繁體中文](https://longbridge.com/zh-HK/news/275095758.md) # LENSAR (NASDAQ:LNSR) Stock Price Up 0.6% - Here's Why LENSAR, Inc. (NASDAQ:LNSR - Get Free Report) rose 0.6% during mid-day trading on Thursday . The stock traded as high as $12.66 and last traded at $12.28. Approximately 113,489 shares changed hands during mid-day trading, an increase of 262% from the average daily volume of 31,360 shares. The stock had previously closed at $12.21. ## Wall Street Analyst Weigh In Several brokerages have recently weighed in on LNSR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of LENSAR in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of LENSAR to a "hold" rating in a research note on Friday, November 28th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus price target of $15.00. **View Our Latest Stock Report on LNSR** ## LENSAR Stock Performance The business's 50 day moving average price is $11.77 and its 200-day moving average price is $11.95. The firm has a market cap of $146.68 million, a price-to-earnings ratio of -2.80 and a beta of 0.69. LENSAR (NASDAQ:LNSR - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.23). The company had revenue of $14.32 million during the quarter, compared to analyst estimates of $17.75 million. ## Institutional Trading of LENSAR Several institutional investors have recently added to or reduced their stakes in the business. Brandes Investment Partners LP lifted its position in shares of LENSAR by 3.5% in the 2nd quarter. Brandes Investment Partners LP now owns 563,581 shares of the company's stock worth $7,422,000 after buying an additional 18,894 shares during the last quarter. Vanguard Group Inc. raised its stake in LENSAR by 0.3% during the third quarter. Vanguard Group Inc. now owns 507,603 shares of the company's stock worth $6,269,000 after acquiring an additional 1,446 shares during the period. Groupe la Francaise lifted its holdings in LENSAR by 99.5% in the second quarter. Groupe la Francaise now owns 251,400 shares of the company's stock worth $3,311,000 after acquiring an additional 125,400 shares during the last quarter. Geode Capital Management LLC boosted its stake in LENSAR by 103.9% in the second quarter. Geode Capital Management LLC now owns 219,373 shares of the company's stock valued at $2,890,000 after acquiring an additional 111,802 shares during the period. Finally, Credit Industriel ET Commercial boosted its stake in LENSAR by 98.4% in the second quarter. Credit Industriel ET Commercial now owns 168,600 shares of the company's stock valued at $2,220,000 after acquiring an additional 83,600 shares during the period. Institutional investors own 40.15% of the company's stock. ## About LENSAR (Get Free Report) LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions. Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment. ## Featured Stories - Five stocks we like better than LENSAR - “Fed Proof” Your Bank Account with THESE 4 Simple Steps - When to buy gold (mathematically) - NEW LAW: Congress Approves Setup For Digital Dollar? - EXPOSED: The “29% Account” - Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in LENSAR Right Now? Before you consider LENSAR, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list. While LENSAR currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md) - [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md) - [LENSAR, Inc. (LNSR.US)](https://longbridge.com/en/quote/LNSR.US.md) ## Related News & Research - [Geoffrey Beran Rose Sells 7,732 Shares of Pulmonx (NASDAQ:LUNG) Stock](https://longbridge.com/en/news/277978473.md) - [Pulmonx Q4 revenue beats expectations](https://longbridge.com/en/news/277833961.md) - [Enovis Corporation $ENOV Shares Sold by Royce & Associates LP](https://longbridge.com/en/news/277474498.md) - [10:10 ETLRS SECURES IDE TO STUDY ITS THERMOSUIT COOLING DEVICE IN A PIVOTAL TRIAL OF ISCHEMIC STROKE PATIENTS](https://longbridge.com/en/news/277488497.md) - [Andra AP fonden Buys 18,900 Shares of Boston Scientific Corporation $BSX](https://longbridge.com/en/news/277428447.md)